Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2025-01-13 Earnings Release
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: CROISSANCE DE L’ACTIVITE EN 2024 - POURSUITE DE LA RESTRUCTURATION DU GROUPE EN 2024
Earnings Release Classification · 99% confidence The document presents key financial highlights for the year 2024, including revenue figures (Chiffre d'affaires 2024 : 101,4 M€), divisional breakdowns, and significant operational updates (restructuring, debt renegotiation, site closures). It explicitly states that the figures are 'non audités' (unaudited) and announces the upcoming 'Résultats annuels 2024 le 23 avril 2025'. This structure—providing preliminary, unaudited results before the official annual filing—is characteristic of an Earnings Release (ER), which typically contains key highlights before the full 10-K or comprehensive Annual Report (AR) is published. It is not the full Annual Report (10-K) because the figures are unaudited and it serves as a preliminary announcement. It is too detailed for just a Report Publication Announcement (RPA) as it contains substantial financial data and commentary. FY 2024
2025-01-13 French
BIOSYNEX SA: CROISSANCE DE LACTIVITE EN 2024 - POURSUITE DE LA RESTRUCTURATION DU GROUPE EN 2024
Earnings Release Classification · 100% confidence The document is a press release dated January 13, 2025, detailing the 'CROISSANCE DE L’ACTIVITE EN 2024' (Activity Growth in 2024) and providing key unaudited financial figures for the full year 2024 (Revenue: 101.4 M€). It also mentions restructuring activities and debt renegotiation. This content aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, typically highlighting key figures before the full, audited report (like the 10-K or IR). The document explicitly states that the 'Prochaine communication : Résultats annuels 2024 le 23 avril 2025 après bourse' (Next communication: Annual results 2024 on April 23, 2025), confirming this is a preliminary/initial release of results, not the comprehensive Annual Report (10-K) or Interim Report (IR). FY 2024
2025-01-13 French
BIOSYNEX SA: Calendrier financier 2025
Report Publication Announcement Classification · 99% confidence The document is titled "Calendrier financier 2025" (Financial Calendar 2025) and explicitly lists future dates for key financial publications, such as 'Chiffre d'affaires annuel 2024' (Annual Revenue 2024) and 'Résultats annuels 2024' (Annual Results 2024). This is an announcement detailing the schedule for future corporate reporting events, not the reports themselves. Since it is an announcement about the timing and publication of future reports, it fits best under 'Report Publication Announcement' (RPA). The document length (3220 chars) is short, supporting the idea that it is an announcement rather than a full report (like 10-K or IR).
2024-12-19 French
BIOSYNEX ANNONCE AVOIR TROUVE UN ACCORD DE PRINCIPE AVEC SES PRINCIPAUX CREANCIERS SUR LES TERMES DU REAMENAGEMENT DE SON ENDETTEMENT FINANCIER PROJET D’AUGMENTATION DE CAPITAL
Capital/Financing Update Classification · 98% confidence The document is a press release announcing a major financial restructuring agreement ('Accord de Principe') with creditors, involving debt rescheduling and a planned capital increase ('projet d'augmentation de capital'). It details the terms of debt modification (consolidation, maturity extensions, payment holidays) and the specifics of the upcoming equity raise, including shareholder commitments and regulatory implications (AMF filing exemption, potential mandatory tender offer threshold crossing). The text explicitly mentions that the Board of Directors has convened a General Meeting ('Assemblée Générale des actionnaires') to vote on the capital increase. Since this document announces significant financing activities (debt restructuring and capital increase) and related corporate actions, it falls under the 'Capital/Financing Update' category. It is not a full annual report (10-K), an interim report (IR), or just an earnings release (ER). It is a comprehensive announcement of financing terms.
2024-12-02 French
BIOSYNEX SA: DECLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 31 OCTOBRE 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 OCTOBRE 2024" (Declaration of the number of shares and voting rights as of October 31, 2024). It explicitly references French regulatory articles (Article L.233-8 II du Code de commerce – Article 223-16 du Règlement général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and net voting rights. This content directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), which covers official results from shareholder votes or related statutory disclosures on voting rights.
2024-11-04 French
BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Chembio Diagnostics (a subsidiary of Biosynex) has been awarded a grant from the Bill & Melinda Gates Foundation. It details the nature of the grant, the technology being developed, and provides background information on the company. It does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement (RPA) as it is the primary announcement itself. Therefore, it falls under the general regulatory/corporate announcement category.
2024-10-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.